© 2025 by Trienix Pharma. Powered and secured by Wix
Pipeline
Pain control
(non-opioid)
We are developing safe, non-addictive therapies for post-operative and neuropathic pain by promoting resolution of inflammation without the risks associated with opioids or NSAIDs. Unlike conventional analgesics, our compounds act upstream to resolve inflammation and accelerate recovery. This approach supports opioid-sparing strategies while addressing the urgent need for effective alternatives in both acute and chronic pain care.
MASLD/MASH
(diabetes)
Our drug candidates aim to slow or reverse the progression of metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH). Through resolution pharmacology, we address the root drivers of hepatocellular stress and fibrogenesis without compromising immune function. This first-in-class mechanism offers a chronic, non-invasive treatment approach for a growing global health burden lacking approved therapies.
Viral infections (H1N1/H5N1)
We are developing Protectin DX analogs with dual antiviral and inflammation-resolving properties for use in severe viral infections, such as avian influenza (H5N1). By engaging GPR37, our compounds limit cytokine storm–induced damage while preserving host defense mechanisms. This strategy is designed to mitigate acute lung injury and improve survival outcomes in viral infections with high mortality and limited therapeutic options.